Adimab, LLC, a technology leader in the discovery of fully human antibodies and bispecifics, today announced that GlaxoSmithKline (GSK) has broadened its relationship with Adimab. Under an expanded collaboration, Adimab will build a unique custom library for GSK for use in generating bispecific antibody leads. Adimab will use that library as well as existing Adimab technology in collaboration with GSK to discover antibodies against multiple targets and generate bispecific antibodies against combinations of those targets.  Read More